Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenol ethers class. It features an isoxazole ring and a dihydrooxazole moiety connected via a pentyl linker to a phenoxy group. The structure suggests potential for biological activity and interest in medicinal chemistry research. According to DrugBank and other chemical databases, it has been investigated as an experimental compound but has not reached clinical development or approval stages. Its only reported molecular target is the genome polyprotein (a generic viral or genetic target), with no specific disease indication or approved use[1][2][3][7]. No detailed mechanism of action beyond this general targeting has been described.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole.